Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | BDKRB1 | P46663 | 8/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22765066 | 0.86 | TDP1 (0.65) | TDP1BDKRB1L3MBTL1HTTGAA | |
| SCHEMBL26053610 | 0.84 | KMT2A (0.69) | TDP1L3MBTL1HTTMEN1KMT2A | |
| SCHEMBL22765214 | 0.84 | TDP1 (0.50) | TDP1HTTMEN1KMT2AMMP2 | |
| SCHEMBL22765006 | 0.83 | TDP1 (0.60) | TDP1HTTMEN1KMT2AMMP2 | |
| SCHEMBL22765113 | 0.83 | TDP1 (0.54) | TDP1HTTMEN1KMT2AMMP2 | |
| SCHEMBL22765051 | 0.81 | SLC40A1 (0.63) | TDP1HTTMEN1KMT2AMMP2 | |
| SCHEMBL13485939 | 0.80 | TDP1 (1.00) | TDP1L3MBTL1HTTMEN1KMT2A | |
| SCHEMBL22765016 | 0.78 | SLC40A1 (0.52) | TDP1MEN1KMT2AMMP2 | |
| SCHEMBL30471589 | 0.77 | SLC40A1 (0.58) | TDP1HTTMEN1KMT2AMMP2 | |
| SCHEMBL22764936 | 0.77 | SLC40A1 (0.58) | TDP1HTTMEN1KMT2AMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | OTAGO INNOVATION LIMITED (NZ) | 2023-07-04 | — | — | US | disclosed |
| US-20200385354-A1 | Quinoline Sulfonamide Compounds and Their Use as Antibacterial Agents | OTAGO INNOVATION LIMITED (NZ) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | NQO2, SDHA, SIRT5 | TDP1 4605/4885BDKRB1 4137/4885L3MBTL1 4089/4885 |
| US-20200385354-A1 | Quinoline Sulfonamide Compounds and Their Use as Antibacterial Agents | NQO2, SDHA, SIRT5 | TDP1 4605/4885BDKRB1 4137/4885L3MBTL1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.